Senior Director, Group Leader, Specialty Access Solutions Pfizer, Inc
Chris has 22 years of experience in the healthcare industry across the provider, payer, and pharmaceutical sectors. He is currently Senior Director, Group Leader, Specialty Access Solutions (SAS) at Pfizer, Inc. He began his career back in 1992 as the Executive Director of REMEDY, Inc., an international medical relief agency start up and still participates as a member of the Board of Directors today. Five years later, Chris joined Ernst & Young as a Senior Consultant in their Healthcare Provider Practice developing strategic solutions for medical practices and newly formed integrated delivery systems. In 2000, he branched out on his own again to form HealthInfo Corp, a streaming media start-up that provided online medical education for both providers and patients.
Chris then transitioned back into consulting and joined Deloitte as a Manager in their Payer Practice, where his MCO & PBM experience began. This consulting network eventually landed him a position at WellPoint, Inc. in 2002, where he worked for the next six years helping to build their strategic planning and project execution competencies. Chris rose to Staff Vice President in 2005, managing their Center’s of Business Excellence to drive the identification and adoption of best practices across their 14 states (following the Anthem, Inc. and WellPoint, Inc. merger).
In 2008, Chris looked to round out his healthcare industry experience, this time in pharmaceuticals, and joined Pfizer, Inc. as a Senior Director in U.S. Payers and National Accounts. Chris managed a team of National Account Managers responsible for product access and performance across many different channels including Health Plans, PBMs, Specialty Pharmacy, Federal (VA & DoD), and Long-Term-Care.
In 2011, Chris brought his managed markets experience to Pfizer’s Oncology business unit, as the Group Leader for Oncology Managed Markets, leading a team of Oncology National Account Managers to optimize the access and performance of Pfizer’s growing Oncology portfolio.
In 2014, Chris is now part of Pfizer’s U.S. Payer & Channel Access platform, where his SAS team is responsible for Pfizer’s full portfolio of Specialty Pharmacy interactions as well as national payer access for the Oncology portfolio.
Chris graduated from the University of Vermont with a BA in Psychology and a pre-med concentration in 1992. He completed his MPH at Yale University with a concentration in Healthcare Management in 1997, and has called New York City home for the past 7 years.